[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.166.22. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
July 2003

Treatment of Melanoma In Situ on Sun-Damaged Skin With Topical 5% Imiquimod Cream Complicated by the Development of Invasive Disease

Author Affiliations

Not Available

Arch Dermatol. 2003;139(7):945-947. doi:10.1001/archderm.139.7.945

Melanoma in situ (MIS) arising on chronically sun-damaged skin (also known as lentigo maligna) usually presents as a large hyperpigmented patch on the face of elderly patients. While MIS is itself a nonlethal neoplasm, it can develop foci of invasive disease that can carry the same prognostic implications as those associated with any invasive melanoma.1

Recently, Ahmen and Berth-Jones2 reported successfully treating a case of MIS on sun-damaged skin with topical 5% imiquimod cream. Based on the success of Ahmen and Berth-Jones, we treated our patient's large, recurrent MIS with topical imiquimod. We observed a clearance of the MIS. However, our patient's clinical course was complicated by the development of invasive amelanotic melanoma with satellite lesions.

×